Marketer: Cipla Limited
(Bold for FDA approved)
• Binds to benzodiazepine receptors at the GABA-A ligand-gated chloride channel complex
• Enhances the inhibitory effects of GABA
• Boosts chloride conductance through GABA-regulated channels
• Inhibits neuronal activity presumably in amygdala-centered fear circuits to provide therapeutic benefits in anxiety disorders
• Some immediate relief with first dosing is common; can take several weeks with daily dosing for maximal therapeutic benefit
✽ Sedation, fatigue, depression ✽ Dizziness, ataxia, slurred speech, weakness ✽ Forgetfulness, confusion ✽ Hyperexcitability, nervousness
• Rare hallucinations, mania
• Rare hypotension
• Hypersalivation, dry mouth
• Respiratory depression, especially when taken with CNS depressants in overdose
• Rare hepatic dysfunction, renal dysfunction, blood dyscrasias
unusual
not usual
• Wait
• Wait
• Wait
• Lower the dose
• Switch to alprazolam XR
• Take largest dose at bedtime to avoid sedative effects during the day
• Switch to another agent
• Administer flumazenil if side effects are severe or life-threatening
• Anxiety: alprazolam IR: 1–4 mg/day
• Panic: alprazolam IR: 5–6 mg/day
• Panic: alprazolam XR: 3–6 mg/day
• Alprazolam IR tablet 0.25 mg scored, 0.5 mg scored, 0.8 mg, 1 mg scored, 2 mg multiscored
• Alprazolam IR orally disintegrating tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg
• Alprazolam XR (extended-release) tablet 0.5 mg, 1 mg, 2 mg, 3 mg
• Risk of dependence, particularly for treatment periods longer than 12 weeks and especially in patients with past or current polysubstance abuse
• Alprazolam is a Schedule IV drug
• Patients may develop dependence and/or tolerance with long-term use
• Drug should be used with caution
• Should begin with lower starting dose (0.5–0.75 mg/day in 2 or 3 divided doses)
• Benzodiazepines have been used to treat anxiety associated with acute myocardial infarction
• Should begin with lower starting dose (0.5–0.75 mg/day in 2 or 3 divided doses) and be monitored closely
• Safety and efficacy not established but often used, especially short-term and at the lower end of the dosing scale
• Long-term effects of alprazolam in children/adolescents are unknown
• Should generally receive lower doses and be more closely monitored
• Risk Category D [positive evidence of risk to human fetus; potential benefits may still justify its use during pregnancy]
• Possible increased risk of birth defects when benzodiazepines taken during pregnancy
• Because of the potential risks, alprazolam is not generally recommended as treatment for anxiety during pregnancy, especially during the first trimester
• Drug should be tapered if discontinued
• Infants whose mothers received a benzodiazepine late in pregnancy may experience withdrawal effects
• Neonatal flaccidity has been reported in infants whose mothers took a benzodiazepine during pregnancy
• Seizures, even mild seizures, may cause harm to the embryo/fetus
• Some drug is found in mother’s breast milk ✽ Recommended either to discontinue drug or bottle feed
• Effects on infant have been observed and include feeding difficulties, sedation, and weight loss
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera